Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
Nguyen, L. C.; Yang, D.; Nicolaescu, V.; Best, T.; Chen, S.; Friesen, J. B.; Drayman, N.; Mohamed, A.; Dann, C.; Silva, D.; Gula, H.; Jones, K. A.; Millis, J. M.; Dickinson, B. C.; Tay, S.; Oakes, S. A.; Pauli, G. F.; Meltzer, D. O.; Randall, G.; Rosner, M. R.
Show abstract
The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway. A cohort of human patients previously taking CBD had significantly lower SARS-CoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population. This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Post-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection 95%
- More than just an Eagle Killer: The freshwater cyanobacterium Aetokthonos hydrillicola produces highly toxic dolastatin derivatives 93%
- 2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses 93%
Similar papers in this journal
- Somatostatin venom analogs evolved by fish-hunting cone snails: From prey capture behavior to identifying drug leads 94%
- The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy 93%
- Enterovirus Evolution Reveals the Mechanism of an RNA-Targeted Antiviral and Determinants of Viral Replication 93%
Similar papers in this journal
- JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis 95%
- The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication 95%
- A vimentin-targeting oral compound with host-directed antiviral and anti-inflammatory actions addresses multiple features of COVID-19 and related diseases 94%
Similar papers in this journal
Similar papers in this journal
- Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases 95%
- AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans 93%
- Antibodies targeting Crimean-Congo hemorrhagic fever virus GP38 limit vascular leak and viral spread 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.